Medicinally useful proteins - Enhancing the probability of technical success in the clinic

Expert Opinion on Biological Therapy

Volumn 5, Issue 2, 2005, Pages 149-151

  Shanafelt, Armen B ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Biopharmaceutical; Bioproduct; Clinical development; Lead optimisation; Mutein; Optimisation strategy; Protein mutagenesis; Protein therapeutic

Indexed keywords

PEPTIDE; PROTEIN;

AMINO ACID SEQUENCE; BIOLOGICAL ACTIVITY; CELL ACTIVATION; CELL COMPARTMENTALIZATION; CELL INTERACTION; CELL TYPE; DRUG MECHANISM; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; PATIENT COMPLIANCE; PROTEIN FUNCTION; QUALITY CONTROL; REVIEW; SOLUBILITY; TARGET CELL; VALIDATION PROCESS; WILD TYPE;

HUMANS; PHARMACEUTICAL PREPARATIONS; PROBABILITY; PROTEINS;

EID: 15244359865     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.5.2.149     Document Type: Review

References (3)

1. SHANAFELT AB, LIN Y, SHANAFELT MC et al.: A T cell-selective IL-2 mutein exhibits potent antitumour activity and is well-tolerated in vivo. Nat. Biotech. (2000) 18(11):1197-1202.
2. BAERT F, NOMAN M, VERMEIRE S et al.: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. (2003) 348:601-608.
3. CEFALU WT: Concept, strategies, and feasibility of noninvasive insulin delivery. Diabetes Care (2004) 27:239-246.